

VetComp

Giant Dogs, Giant Problems? Primary-care disorder burden in UK giant breed dogs, with a focus on Neoplasia.

T. Curtis, D. Brodbelt, D. Church, D. O'Neill

Royal Veterinary College



tcurtis20@rvc.ac.uk

Background: Giant breed dogs, such as Great Danes and Alaskan Malamutes, are known for their size but also their health challenges and shorter lifespans. Understanding the demography, morbidity and mortality of giant breed dogs is crucial for improving health and welfare. Neoplasia is a leading cause of morbidity and mortality in dogs worldwide^{1,3}. Giant dog breeds are reported to have a higher neoplastic prevalence compared to non-giant breeds, suggesting a genetic predisposition^{3, 4}.

Aims: To report the demography and identify the most common causes of morbidity and mortality in giant breed dogs in the UK, with a specific focus on neoplasia.

Hypotheses: 'Female giant dogs have higher odds of a neoplasia than male giant breed dogs' and 'Giant dogs have higher odds of a dermatological mass/neoplasia compared with other body systems'.

Inclusion criteria: Giant breeds are described in literature as 'having an adult weight of >50kg and a shoulder height of >63cm'². **Data collection:** Deidentified patient data were extracted from the VetCompass[™] database. Data available included date of birth, species, breed, sex, and neuter status along with all clinical records.

Demography: The study incorporated 28,345 dogs across 28 giant breeds. The median age was 4.32 years (IQR) 1.84-7.37)). Mean adult bodyweight was 58.05kgs (IQR 53.71-64.80). The most common giant breed was Dogue de Bordeaux (n=5156, 18.19%).

Morbidity: Overall, 7419 specific-focus level disorders were recorded during 2019 across a random sample of 4300 dogs.

The most common specific-level disorders are listed in Table 1.


Mortality:

24.81% (n=1,067) giant dogs died during 2019. Mean age at death was 7.68 years (IQR 5.33-9.99). Mean age at death (n=507) was 7.35 (±3.09 SD) years for

Morbidity (n=4300)			Mortality (n=1067)		
Disorder	%	95% CI	Disorder	%	95% CI
Otitis externa	4.74	4.28-5.25	Undiagnosed	44.05	41.10-47.04
Obesity	4.66	4.21-5.17	Collapsed	9.37	7.77-11.27
Aggression	3.23	2.86-3.63	Aggression	3.47	2.53-4.74
Dental Disease	3.21	2.83-3.53	Bone Neoplasm	3.19	2.29-4.42
Overgrown nails	3.11	2.74-3.53	Poor Quality of Life	2.53	1.74-3.66
Table 1: The most common specific-level disorders and reasons for mortality, from giant breed					
dogs, in VetCompass™ Programme, under primary veterinary care.					

Disorder	%	95% CI	Disorder	%	95% CI
Skin Cyst	13.51	10.38-17.41	Mammary Neoplasm	3.97	2.40-6.51
Lipoma	8.74	6.26-12.09	Limb Mass	3.02	1.69-5.33
Skin Mass	5.88	3.90-8.79	Multiple Masses	2.86	1.58-5.13
Papilloma	4.61	2.89-7.28	Bone Neoplasia	2.72	1.47-4.93
Skin Polyp	4.29	2.64-6.89	Epulis	2.54	1.36-4.72
Table 2. The 10 most common diagnosed mass/neonlastic disorders recorded from A 300 giant					

Table 2: The 10 most common diagnosed mass/neoplastic disorders recorded from 4, 300 giant breed dogs in the VetCompassTM Programme, under primary veterinary care.



Multivariable analysis: **Neoplasia:** Odds of neoplasia compared to 12.47% (n=536) giant dogs were **Dogue de Bordeaux:** diagnosed with a mass or neoplasia [Table. 2]. **Giant Schnauzers had higher odds** (OR=1.79, 95% CI 1.02-3.14). 277 (51.68%) were female, 259 (48.13%) were male. Alaskan Malamutes (OR 0.40, 95%) CI 0.28-0.58) and Newfoundland The mean age of giant dogs with a Dogs (OR 0.36, 95% CI 0.22-0.57) diagnosis was 7.23 (±3.05) years. had lower odds. **Dermatologic mass/neoplasia was** Multivariable analysis included 3 the most commonly diagnosed variables: age, breed, and location (32.59%) [Fig. 1]. bodyweight [Table. 3]. *Note: Table* 3 does not show breed. Variable Odds Ratio 95% CI Category Category (P-value) Variable (P-value) Bodvweight < 0.001 0 to < 40Base

Conclusion: High morbidity and mortality underscores the welfare importance of neoplasia in giant breed dogs. These results can assist veterinarians to update their clinical reasoning, kennel clubs to update current breed health plans, and provide useful information for breeders when selecting animals to prioritise breed health.

primary veterinary care in the VetCompass™ Programme during 2019, in the UK.

References:

1. Favier, R. P., et al. (2001). "Large body size in the dog is associated with transient GH excess at a young age." *J Endocrinol* 170(2): 479-484.

2. Galis, F., et al. (2007). "Do large dogs die young?" J Exp Zool B Mol Dev Evol 308(2): 119-126.

3. Gough, A. T. a. D. O. N. (2018). Breed Predisposition to Disease in Dogs and Cats. Oxford, UK, John Wiley & Sons Ltd.

4. Ujvari, B., et al. (2018). "Genetic diversity, inbreeding and cancer." *Proc Biol Sci* 285(1875).

Douyweight	0.00 < 40	Dase			~0.00T
(kg)	40 to < 60	1.11	0.82-1.50	0.488	
	60 to < 80	0.97	0.65-1.46	0.885	
	≥ 80	1.36	0.40-4.62	0.627	
	Uncategorised	0.54	0.38-0.76	<0.001	
Age (years)	< 5	Base			< 0.001
	5 to < 8	3.54	2.73-4.57	<0.001	
	8 to < 12	7.37	5.70-9.54	<0.001	
	≥ 12	6.45	3.92-	<0.001	
			10.61		
	Uncategorised	~			
<u>I</u>	I				I

Table 3: Multivariable logistic regression results for non-breed related risk factors for developing

 mass/neoplasia in giant breed dogs, in 2019, under primary veterinary care, in the UK.